Vela Diagnostics has announced expanded automation for its ViroKey SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) Test v2.0, which can now be used with the Hamilton Microlab STAR platforms and KingFisher FLEX system.

The US Food and Drug Administration (FDA) granted emergency use authorisation (EUA) to the test.

Now operating with the KingFisher FLEX, the test will have a lower turnaround time and boosted sample throughput while preserving the SA201 Reporter of the company and offering clinically significant reports to pathologists.

Vela also provides the Hamilton Microlab STAR test option, which possesses a throughput of 376 samples in one run.

The company noted that the PCR is still being carried out on the Sentosa SA201 and, in combination with the SA201 Reporter, offers quick and precise reporting.

Vela Diagnostics executive vice-president Steven Wallace said: “The Hamilton Microlab STAR workflow option comes at a time when many of our customers are still ramping up Covid-19 testing.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This high-throughput workflow will allow laboratories to process substantially more samples per day, with less hands-on time and reduced labour cost.”

The company presented the workflow test data for the two new options to the FDA and it has been accepted as an addition to the test’s EUA.

The FDA has not yet examined the updated test data of ViroKey SARS-CoV-2 RT-PCR Test v2.0, but the product revisions are under review.

Commercial availability of the test’s new options in US markets is granted under the EUA distribution policies of the FDA.

The new workflows of the company complement its currently available sample-to-result solutions, such as the next-generation sequencing (NGS) workflow utilised for the Sentosa SQ HIV-1 Genotyping Assay (IVD) on the Sentosa SQ301.

In March, the company announced the addition of ViroKey SQ FLEX SARS-CoV-2 Genotyping Assay and ViroKey SARS-CoV-2 ID RT-PCR Test to its portfolio offering for Covid-19 testing.